United Therapeutics Corp (NASDAQ:UTHR) Chairperson and CEO Martine A. Rothblatt executed a pre-arranged sale of 9,500 shares on June 29, 2026, generating approximately $5.18 million. This transaction, part of a broader 10b5-1 plan established in late 2025, involved the exercise of stock options and subsequent liquidation. The sale occurs against a backdrop of significant corporate milestones, including regulatory approvals and clinical trial successes, highlighting the intersection of executive compensation mechanics and biopharmaceutical operational progress.
The transaction details reveal that Rothblatt sold the shares at prices ranging from $539.47 to $549.17 per share. These sales followed the exercise of 9,500 stock options at an exercise price of $135.42 per share, representing an acquisition cost of $1,286,489. Both the option exercise and the subsequent sale of common stock were conducted under a pre-arranged 10b5-1 trading plan. This plan was adopted by Ms. Rothblatt on November 7, 2025, and is set to continue until either 1,734,410 stock options (all expiring on March 15, 2027) have been exercised, or December 31, 2026, whichever occurs first.
Following these transactions, Ms. Rothblatt directly holds 40,513 shares of United Therapeutics common stock. Her indirect holdings include 166 shares held by her spouse, and a combined 628,049 shares held across various family trusts. These trusts involve shared investment power with Ms. Rothblatt and/or immediate family beneficiaries, or are managed by her spouse as sole trustee/beneficiary or co-trustee/settlor with the power to revoke.
Additionally, Ms. Rothblatt holds 96,718 directly owned stock options and 349,192 stock options indirectly through a family trust, where she shares investment power and is a beneficiary along with immediate family members. Despite the insider sale, InvestingPro data shows United Therapeutics maintains a "GREAT" financial health score, with the company holding more cash than debt and boasting gross profit margins of 87%. Investors can access the comprehensive Pro Research Report for UTHR, one of 1,400+ US equities covered, for deeper analysis.
In other recent news, United Therapeutics Corporation received premarket approval from the U.S. Food and Drug Administration for its LungFX device, designed for centralized ex vivo lung perfusion. This approval allows for the assessment of donor lungs outside the body prior to transplantation. Additionally, United Therapeutics announced that its TETON-1 phase 3 study of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint, demonstrating preserved lung function and a reduced risk of clinical worsening events. The results were published in the New England Journal of Medicine.
Furthermore, TD Cowen reiterated a Buy rating on United Therapeutics stock, setting a price target of $675.00. This reiteration follows an investor lunch with a leading pulmonologist involved in the TETON studies. In another development, United Therapeutics partnered with Varda Space Industries to explore microgravity-based pharmaceutical processing for rare pulmonary diseases. The collaboration will leverage microgravity to enhance the stability, bioavailability, and delivery characteristics of therapeutic compounds. These recent developments highlight significant advancements and strategic partnerships for United Therapeutics.